Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) EPS (Basic) (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed EPS (Basic) for 16 consecutive years, with -$0.03 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 72.73% to -$0.03 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.52, a 360.61% decrease, with the full-year FY2024 number at -$0.28, down 250.0% from a year prior.
  • EPS (Basic) was -$0.03 for Q3 2025 at Harvard Bioscience, up from -$0.05 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.06 in Q2 2022 to a low of -$1.14 in Q1 2025.
  • A 5-year average of -$0.11 and a median of -$0.04 in 2023 define the central range for EPS (Basic).
  • Biggest YoY gain for EPS (Basic) was 700.0% in 2022; the steepest drop was 1791.86% in 2022.
  • Harvard Bioscience's EPS (Basic) stood at $0.02 in 2021, then plummeted by 300.0% to -$0.04 in 2022, then rose by 0.0% to -$0.04 in 2023, then plummeted by 650.0% to -$0.3 in 2024, then skyrocketed by 90.0% to -$0.03 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's EPS (Basic) are -$0.03 (Q3 2025), -$0.05 (Q2 2025), and -$1.14 (Q1 2025).